Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine

By sjmartinez • April 27, 2023

Hendershot A, Slabaugh M, Riaz KM, Moore KN, O'Malley DM, Matulonis U, Konecny GE. Strategies for prevention and management of ocular events occurring with mirvetuximab soravtansine. Gynecol Oncol Rep. 2023 Feb 28;47:101155. doi: 10.1016/j.gore.2023.101155. PMID: 37102083; PMCID: PMC10123335.

Tags: Antibody-drug conjugates, Eye care, Folate receptor alpha, Hematology/Oncology, Mirvetuximab soravtansine, Ocular adverse events, ovarian cancer, Publications

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results

Wainberg ZA, Weekes CD, Furqan M, Kasi PM, Devoe CE, Leal AD, Chung V, Perry JR, Kheoh T, McNeil LK, Welkowsky E, DeMuth PC, Haqq[...]

Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patients

Moore TW, Spiliotopoulos E, Callahan RL, Kirschbaum CW, Bailey CF, Kim HJ, Roskams-Hieter B, Goncalves F, Keith D, Grossberg AJ, Spellman PT, Mills GB, Sears[...]

US expert Delphi consensus on the prevention and management of stomatitis in patients treated with datopotamab deruxtecan

Rugo H, Bardia A, Bruno DS, Ernani V, Hamilton E, Heist R, Jhaveri K, Levy B, Lisberg A, O'Shaughnessy J, Sands J, Spira A, Tolaney[...]